CeriBell, Inc (CBLL) - Net Assets
Based on the latest financial reports, CeriBell, Inc (CBLL) has net assets worth $155.34 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($195.80 Million) and total liabilities ($40.47 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are CeriBell, Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $155.34 Million |
| % of Total Assets | 79.33% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CeriBell, Inc - Net Assets Trend (2022–2025)
This chart illustrates how CeriBell, Inc's net assets have evolved over time, based on quarterly financial data. Also explore CBLL total asset value for the complete picture of this company's asset base.
Annual Net Assets for CeriBell, Inc (2022–2025)
The table below shows the annual net assets of CeriBell, Inc from 2022 to 2025. For live valuation and market cap data, see CBLL market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $155.34 Million | -18.74% |
| 2024-12-31 | $191.16 Million | +270.30% |
| 2023-12-31 | $-112.25 Million | -29.92% |
| 2022-12-31 | $-86.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CeriBell, Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12333100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $38.00K | 0.02% |
| Other Comprehensive Income | $159.00K | 0.10% |
| Other Components | $375.50 Million | 241.73% |
| Total Equity | $155.34 Million | 100.00% |
CeriBell, Inc Competitors by Market Cap
The table below lists competitors of CeriBell, Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Jinji Industrial Co Ltd
SHE:300798
|
$699.13 Million |
|
Salim Ivomas Pratama Tbk
JK:SIMP
|
$699.40 Million |
|
Fidus Investment Corp
NASDAQ:FDUS
|
$699.41 Million |
|
Basilea Pharmaceutica AG
SW:BSLN
|
$699.48 Million |
|
Shenzhen Refond Optoelectronics Co Ltd
SHE:300241
|
$698.85 Million |
|
Zhejiang Fuchunjiang Environmental Thermoelectric Co Ltd
SHE:002479
|
$698.70 Million |
|
Zhuhai Port Co Ltd
SHE:000507
|
$698.50 Million |
|
Kossan Rubber Industries Bhd
KLSE:7153
|
$698.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CeriBell, Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 191,165,000 to 155,336,000, a change of -35,829,000 (-18.7%).
- Net loss of 53,412,000 reduced equity.
- Other comprehensive income increased equity by 159,000.
- Other factors increased equity by 17,424,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-53.41 Million | -34.38% |
| Other Comprehensive Income | $159.00K | +0.1% |
| Other Changes | $17.42 Million | +11.22% |
| Total Change | $- | -18.74% |
Book Value vs Market Value Analysis
This analysis compares CeriBell, Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.82x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-3.70 | $20.50 | x |
| 2023-12-31 | $-4.81 | $20.50 | x |
| 2024-12-31 | $16.00 | $20.50 | x |
| 2025-12-31 | $4.25 | $20.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CeriBell, Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -59.97%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.26x
- Recent ROE (-34.38%) is below the historical average (-13.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | -143.37% | 0.30x | 0.00x | $-28.52 Million |
| 2023 | 0.00% | -65.15% | 0.77x | 0.00x | $-18.24 Million |
| 2024 | -21.16% | -61.82% | 0.29x | 1.18x | $-59.57 Million |
| 2025 | -34.38% | -59.97% | 0.45x | 1.26x | $-68.95 Million |
Industry Comparison
This section compares CeriBell, Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CeriBell, Inc (CBLL) | $155.34 Million | 0.00% | 0.26x | $699.00 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About CeriBell, Inc
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly t… Read more